Ethan Russo, MD along with Michelle Sexton, ND and Carrie Cuttler, PhD have designed a survey to gather information on those utilizing cannabigerol (CBG), a “minor cannabinoid” from cannabis. The survey is put on by Washington State University.
The study is for USA-based adult (21 years and up) patients who have utilized CBG-predominant preparations of cannabis within the last six months. A CBG based product is defined as one that is entirely CBG or when the CBG ratio to other cannabinoids is greater than 1:1. The survey takes around 15 minutes to complete. Your responses will be kept completely confidential.
Editor’s Note: This survey is now closed. The results of the findings can be found below.